COMMUNIQUÉS West-GlobeNewswire

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
04/08/2026
Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 class CRB-913 [...]
Carbonium Core Reports Rare Earth and Critical Mineral Content in Initial Sample Assay
04/08/2026
Multi-element analysis returns elevated concentrations of both light and heavy rare earth elements, along with a broad suite of industrial metals FREDERICK, Md., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental [...]
Beacon Behavioral Partners Expands National Footprint with First Georgia Partnership
04/08/2026
Physician-led partnership deepens access to behavioral healthcare through partnership with AR Psychiatric & Counseling Center Georgia and strengthens its growing behavioral health network across the nation PLANO, [...]
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
04/08/2026
Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain Strengthens Autonomix’s platform opportunity across oncology, autonomic [...]
ABLi Therapeutics Announces Outcomes from its Parkinson’s-related Biomarker Study Demonstrating Modification of Human Disease with Risvodetinib
04/08/2026
11 tissue, blood, and cerebrospinal fluid biomarkers reflecting the biological cascade of neurodegeneration and neuroinflammation in PD respond in concert to risvodetinib treatment in patients with early untreated [...]
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
04/08/2026
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS, Ga [...]
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators
04/08/2026
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks completion of [...]
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
04/08/2026
Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development [...]
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
04/08/2026
GARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
04/08/2026
~ Former Chief Financial Officer of Arcellx Brings Deep Capital Markets and Biotech Financial Leadership Experience ~ SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), [...]
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
04/08/2026
RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Exagen Inc. Reports Second Quarter 2026 Financial Results
04/08/2026
Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million [...]
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
04/08/2026
Data support ongoing Phase 2 “RENEW” trial First-in-human clinical study produced measurable reductions in multiple markers of lung scarring and inflammation in IPF patients Study confirms LTI-03 was safe and well- [...]
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
04/08/2026
LAWRENCEVILLE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference [...]
FDA clears Healis Therapeutics’ IND for Tyemvers®, Enabling U.S. Neuropsychiatric Trials
04/08/2026
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Healis Therapeutics announced that it has opened an IND with the U.S. FDA for Tyemvers®, a new botulinum toxin type A product. The milestone enables Healis to initiate [...]
Cirrus Therapeutics Strengthens Its Position as a Next-Generation Global Ocular Immunology Leader with Singapore Eye Research Institute (SERI) Collaboration and Additional Financing
04/08/2026
Cirrus deepens expansion into Singapore and the Asia-Pacific region through collaboration with Singapore Eye Research Institute and Duke-NUS Medical School’s Centre for Vision Research to support research, clinical [...]
Medvantx Opens New Louisville Facility Expanding Capacity for Pharmacy Fulfillment
04/08/2026
New pharmacy, developed with UPS Healthcare and iA®, more than doubles Louisville footprint and triples cold-chain capacity to support nationwide medication and medical device fulfillment LOUISVILLE, Ky., Aug. 04, 2026 [...]
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
04/08/2026
Published in Bioengineering, a collaborative study with Taipei Medical University researchers identifies key molecular candidates to help guide the development of regenerative therapies for corneal disease. TAIPEI, [...]
SHY Therapeutics Announces the First Patient Has Been Dosed in Phase 1 Clinical Trial Evaluating SHY-ONC6, a Novel, Oral Proteasome Inhibitor for the Treatment of Solid Tumors
04/08/2026
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- SHY Therapeutics (“SHY” or “the Company”), a clinical-stage biotechnology company developing small molecules that non-covalently target ATPases and GTPases and modulate their [...]

Pages